期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CYP2C9基因多态性与磺酰脲类降糖药药代动力学药效学相关性的研究进展 被引量：7

Recent advance in association between genetic polymorphisms in CYP2C9 and pharmacokinetics and pharmacodynamics of sulphonylureas
在线阅读 下载PDF
导出
摘要 磺酰脲类是目前临床上广泛使用的口服降糖药,在人体内通过具有基因多态性的CYP2C9酶代谢。不同基因型CYP2C9酶代谢活性的差异,是造成患者所需磺酰脲类口服降糖药剂量个体差异大的因素之一。本文综合国内外最新报道,阐述了CYP2C9基因多态性与磺酰脲类口服降糖药药动学、药效学相关性的研究进展,为制定磺酰脲类降糖药的个体化用药方案提供参考。 Sulphonylureas are the initial and most commonly used therapy for type 2 diabetes mellitus. Sulphonylureas are metabolized by CYP2C9, and the CYP2C9 gene has several mutant alleles leading to genetic polymorphisms in humans. The variation of metabolism abilities of different CYP2C9 genotype is one of the reasons why the type 2 diabetes mellitus patients need different doses of sulphonylureas. To offer a guidance for individualizing administration of sulphonylureas, we specify the relationship between genetic polymorphisms in CYP2C9 and the pharmacokinetics and pharmacodynamics of stdphonylureas.
作者 黄作君 黎月玲 黄民
机构地区 广州市红十字会医院临床药学室 中山大学药学院
出处 《中国临床药理学与治疗学》 CAS CSCD 2007年第2期219-223,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 细胞色素P450 2C9 基因多态性 磺酰脲类 药动学 药效学 CYP2C9 genetic polymorphisms sulphonylureas pharmacokinetics pharmacodynamics
分类号 R966 [医药卫生—药理学]
  • 相关文献

参考文献39

  • 1胡绍文.口服降糖药的临床应用[A].见:胡绍文,郭瑞林,童光焕,主编.实用糖尿病学[M].第2版.北京:人民军医出版社,2003:160-166.
  • 2Inzucchi SE.Oral antihyperglycemic therapy for type 2 diabetes:scientific review[J].Jama,2002;287:360-372.
  • 3Christopher DM,Lawrence SP,David CZ,et al.Hypoglycemia in patients with type 2 diabetes mellitus[J].Arch Intern Med,2001;161:1653-1659.
  • 4Julia K,Jürgen B.Clinical consequences of cytochrome P450 2C9 polymorphisms[J].Clin Pharmacol Ther,2005;77:1-16.
  • 5Bae JW,Kim HK,Kim JH,et al.Allele and genotype frequencies of CYP2C9 in a Korean population[J].Br J Clin Pharmacol,2005;60:418-422.
  • 6Nakai K,Habano W,Nakai K,et al.Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations[J].Life Sci,2005;78:107-111.
  • 7李健,文思远,王睿,陈昆,方翼,裴斐,王升启.细胞色素P450CYP2C9基因多态性对甲苯磺丁脲代谢动力学的影响[J].药学学报,2005,40(8):695-699. 被引量：22
  • 8Lee SS,Kim KM,Thi-Le H,et al.Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population[J].Ther Drug Monit,2005;27:208-210.
  • 9Adithan C,Gerard N,Vasu S,et al.Allele and genotype frequency of CYP2C9 in Tamilnadu population[J].Eur J Clin Pharmacol,2003;59:707-709.
  • 10Babaoglu MO,Yasar U,Sandberg M,et al.CYP2C9 genetic variants and losartan oxidation in a Turkish population[J].Eur J Clin Pharmacol,2004;60:337-342.

二级参考文献17

  • 1Miners J O,Birkett D J. Cytochrome P4502C9:an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol, 1998,45(6) :525.
  • 2Lone LH, Kim B. Quantitative determination of tolbutamide and its metabolites in human plasma and urine by high - performance liquid chromatography and UV detection. Ther Drug Monit , 1999,21 (6) :664.
  • 3Lee CR, Pieper JA, Hinderllter AL, et al. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamlde in CYP2C9 hetenyzygotes. Clin Pharmacol Trier ,2002,72 (5) :562.
  • 4Julia K,Steffen B,Ingolf M, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics ,2002,12(2 ) :101.
  • 5.遗传药理学[M].Beijing: Science Press,2001.87.
  • 6Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism [J]. Br J Clin Pharmacol, 1998,45 ( 6 ) : 525 - 538.
  • 7Niemi M, Cascorbi I, Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes [J]. Clin Pharmoacol Ther, 2002,72(3) :326 -332.
  • 8Kirchheiner J, Meineke 1, Steinbach N, et al.Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans [ J ]. Br J Clin Pharmacol, 2003,55( 1 ) :51 -61.
  • 9Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam [ J ]. Clin Pharmacokinet, 1998,34 ( 6 ) :421 - 428.
  • 10Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lomoxicam[ J ]. Eur J Clin Pharmacol, 1996,49 (4) : 305 - 308.

共引文献30

同被引文献63

引证文献7

二级引证文献19

中国临床药理学与治疗学
2007年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部